Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. ••Shetty M, Chowdhury YS. Heart Transplantation Allograft Vasculopathy. [Updated 2023 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555999/ This article was very formative in this review, because it contains the most current, peer-reviewed epidemiological statistics on CAV. Largely, the importance of our review is derived from the vast mortality of CAV, which was quantified based on the contents of this article.
2. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft vasculopathy: a review. Can J Surg. 2005;48(4):319–27.
3. Anyanwu A, Treasure T. Prognosis after heart transplantation: transplants alone cannot be the solution for end stage heart failure. BMJ. 2003;326(7388):509–10. https://doi.org/10.1136/bmj.326.7388.509.
4. ••Pober JS, Chih S, Kobashigawa J, Madsen JC, Tellides G. Cardiac allograft vasculopathy: current review and future research directions. Cardiovasc Res. 2021 Nov 22;117(13):2624-2638. doi: https://doi.org/10.1093/cvr/cvab259. This article was very significant in this review because it outlined the increasing mortality of heart transplant recipients due to CAV as time PT increased. The foundation for the claims on the potential for CAV to be the limiting factor in extending the average life expectancy for heart transplant recipients is derived partially from this article.
5. Chih S, Chong AY, Mielniczuk LM, Bhatt DL, Beanlands RS. Allograft vasculopathy: the Achilles’ heel of heart transplantation. J Am Coll Cardiol. 2016;68(1):80–91. https://doi.org/10.1016/j.jacc.2016.04.033.